For Families

Pharming Clinical Trials

[Phase 3] Study of Efficacy of CDZ173 in Patients With APDS/PASLI*

NCT02435173

[Phase3] Extension to Study of Efficacy of CDZ173 in Patients with APDS/PASLI*

NCT02859727

[Phase 3] Pediatric Patients Aged 4 – 11 Years with APDS*

If interested in participating or to learn more click here.

NCT05438407

To learn more contact Pharming’s Medical Information department via the email below.

Email: pharmingmc@eversana.com

* The safety and efficacy of an investigational drug (CDZ173) has not been established. There is no guarantee that it will receive health authority approval or become commercially available in any country for the use being investigated.

Stay informed

Sign up for APDS updates

PI is also referred to as an Inborn Error of Immunity (IEI).

References:

1. “What Are Clinical Trials and Studies?” National Institute on Aging, U.S. Department of Health and Human Services, 9 Apr. 2020,www.nia.nih.gov/health/what-are-clinical-trials-and-studies